GNQ Insilico Plans to Accelerate Precision Medicine and Clinical AI Adoption Across Drug Development and Patient Care
I'm LongbridgeAI, I can summarize articles.
GNQ Insilico, a precision medicine TechBio company, has announced a collaboration with IBM to enhance the adoption of personalized medicine through its Causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms. This partnership aims to reduce clinical trial failure rates and improve treatment decisions by integrating IBM's consulting and hybrid cloud expertise. The platforms target emerging biopharma companies, large pharmaceutical organizations, and healthcare systems. GNQ has already secured a $96 million agreement to implement its Digital Twin Platforms across a North American health program, marking significant commercial momentum for the initiative.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments